摘要
目的:探讨盐酸托莫西汀胶囊联合哌甲酯应用于注意缺陷多动障碍中的效果及安全性。方法:选取2019年1月—2022年10月南通瑞慈医院收治的102例注意缺陷多动障碍患儿,依照随机数字表法分为常规组(n=51)和观察组(n=51),常规组采用盐酸托莫西汀胶囊治疗,观察组采用盐酸托莫西汀胶囊联合哌甲酯治疗,比较两组反应时间、漏报数,斯诺佩评估量表第四版(SNAP-Ⅳ)评分,临床疗效及不良反应发生率。结果:治疗后,两组反应时间均缩短(P<0.05),且观察组短于常规组(P<0.05)。治疗后,两组漏报数均减少(P<0.05),且观察组少于常规组(P<0.05)。治疗后,两组患儿SNAP-Ⅳ评分均降低(P<0.05),且观察组低于常规组(P<0.05)。观察组总有效率(92.16%)高于常规组(76.47%)(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:盐酸托莫西汀胶囊联合哌甲酯用于治疗注意缺陷多动障碍,能够改善临床症状,疗效显著,且安全可靠。
Objective:To investigate the efficacy and safety of Tomoxetine Hydrochloride Capsules combined with Methylphenidate in the treatment of attention deficit hyperactivity disorder.Method:A total of 102 children with attention deficit hyperactivity disorder admitted to Nantong Rich Hospital from January 2019 to October 2022 were selected and divided into the conventional group(n=51)and the observation group(n=51)according to random number table method.The conventional group was treated with Tomoxetine Hydrochloride Capsules,while the observation group was treated with Tomoxetine Hydrochloride Capsules combined with Methylphenidate.The reaction time and number of omissions,Swanson Nolan and Pelham versionⅣscale(SNAP-Ⅳ)scores,clinical efficacy and incidence of adverse effects of the two groups were compared.Result:After treatment,the reaction time of both groups were shortened(P<0.05),and that of the observation group was shorter than that of the conventional group(P<0.05).After treatment,the number of omissions were decreased in both groups(P<0.05),and that of the observation group was lower than that of the conventional group(P<0.05).After treatment,the SNAP-Ⅳscores were reduced in both groups(P<0.05),and that of the observation group was lower than that of the conventional group(P<0.05).The total effective rate in the observation group(92.16%)was higher than that in the conventional group(76.47%)(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Tomoxetine Hydrochloride Capsules combined with Methylphenidate can improve clinical symptoms in the treatment of attention deficit hyperactivity disorder,and the efficacy is significant,safe and reliable.
作者
唐美玲
赵银梅
徐孝华
TANG Meiling;ZHAO Yinmei;XU Xiaohua(Nantong Rich Hospital,Nantong 226001,China;不详)
出处
《中国医学创新》
CAS
2023年第23期10-13,共4页
Medical Innovation of China
关键词
盐酸托莫西汀胶囊
哌甲酯
注意缺陷多动障碍
Tomoxetine Hydrochloride Capsules
Methylphenidate
Attention deficit hyperactivity disorder